Low‐dose vs. high‐dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome
- 25 October 2011
- journal article
- clinical trial
- Published by Wiley in European Journal of Haematology
- Vol. 88 (3), 249-259
- https://doi.org/10.1111/j.1600-0609.2011.01729.x
Abstract
This multicentre prospective randomised trial compared the efficacy and safety of two doses of thalidomide in patients with relapsed or refractory myeloma. The study was designed to test the non‐inferior efficacy and to confirm the better tolerability of low‐dose thalidomide as compared to a higher dose. Four hundred patients were randomly assigned to receive either 100 or 400 mg/day of thalidomide. Dexamethasone treatment was added in both arms for patients with stable disease or treatment failure at 12 weeks. The primary endpoint was 1‐year overall survival (OS). Thalidomide 100 mg/day was better tolerated than 400 mg/day with less high‐grade somnolence, constipation, nausea/vomiting and peripheral neuropathy (P < 0.001, P = 0.007, P = 0.03 and P = 0.007, respectively). In the per‐protocol population (PP), the estimated 1‐year OS rates were of 74.5% (n = 149) and 67.3% (n = 156) in the 400 and 100 groups, respectively. The upper limit of the difference between these rates was of 15.6% higher than the non‐inferiority acceptable limit of 12.75%, and the hypothesis of non‐inferiority of 100 could not be established (P = 0.14). On the other hand, when intent‐to‐treat (ITT) population was analysed, the non‐inferiority was demonstrated because the 1‐year OS rates were of 72.8% (n = 195) and 68.8% (n = 205) in the same groups, leading to an upper limit of the difference of 11.49% lower than the non‐inferiority acceptable limit. In addition, in patients alive 12 weeks postrandomisation and those who received thalidomide plus dexamethasone, there were no significant differences in response rates, time to progression, progression‐free survival and OS between the two groups. Collectively, low‐dose thalidomide 100 mg/day has significant activity in advanced myeloma with an improved safety profile and can be a good salvage therapy in combination with dexamethasone.Keywords
This publication has 34 references indexed in Scilit:
- Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation ProcedureJournal of Clinical Oncology, 2009
- Thalidomide for treatment of multiple myeloma: 10 years laterBlood, 2008
- Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2006
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaBlood, 2005
- The Current Status of Thalidomide in the Management of Multiple MyelomaActa Haematologica, 2005
- The Future Role of Thalidomide in Multiple MyelomaActa Haematologica, 2005
- Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)Bone Marrow Transplantation, 2004
- Treatment of multiple myelomaBlood, 2004
- Modifications to Therapy for Multiple Myeloma: Pegylated Liposomal Doxorubicin in Combination With Vincristine, Reduced-Dose Dexamethasone, and ThalidomideThe Oncologist, 2003
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999